TriangleWS-CART-CS1 (NCT06185751)
WS-CART-CS1 trial for Multiple Myeloma (NCT06185751). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Multiple myeloma remains incurable, and responses to CAR T therapy aimed at one target, BCMA, often do not last.
The idea: aim CAR T cells at a different target, CS1, also called SLAMF7, which is found in most patients with myeloma. The patient's own T cells are collected and engineered with a CS1 receptor. They are returned after three days of chemotherapy that lowers existing lymphocytes. Patients stay in the hospital for seven days.
This early study looks at safety first, and at early signs of effect. At Washington University in St. Louis, Armin Ghobadi leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.